Table 1

The general characteristics of involved studies.

Author YearNationMean ageMean MMSE scoresNon-AD groupsCSF VLP-1 (ng/ml)Sample Tec.Number
ADNon-ADADNon-ADADNon-ADADNon-AD
Tarawneh 201511USA73.6(8.7)72.1(3.3)26(3.7)29(0.8)Healthy549(177.6)396(66)MBI2364
Mroczko 201612PolandNRNR18(5.6)29(1.5)Healthy107(63.7)41(60)ELISA3318
Mroczko 201612PolandNRNR18(5.6)26(3.2)MCI107(63.7)70(25.7)ELISA3315
Kester 201517Netherlands65(4.8)64(9.6)22(3.4)28(1.5)Healthy182(48.8)168(53.7)MBI6537
Kester 201517Netherlands65(4.8)68(4.8)22(3.4)27(1.5)MCI182(56)192(73)MBI6561
Babić Leko201613Croatia72(8.2)50(9.8)20.1(4.6)27.7(1.7)Healthy147.9(84.8)65.5(49.3)ELISA1099
Babić Leko201613Croatia72(8.2)68(9.8)20.1(4.6)24.9(2.9)MCI147.9(84.8)98.7(80.3)ELISA10943
Luo 201314China68.1(7.6)65.1(6)12.1(3.9)26.3(3.2)Healthy72.1(21.2)43(9.5)ELISA6140
Tarawneh 201115USA74.9(8.1)72.1(7.1)25.3(3.8)28.9(1.3)Healthy520(117)396(149)MBI98211
Lee 200816USA67(6.8)68.5(4.9)23(4.1)29.8(0.4)Healthy368(129)245(113)ELISA3324
  • Data were showed as mean (SD). MMSE - mini-mental state examination, AD - alzheimer’s disease, CSF - cerebrospinal fluid, VLP-1 - visinin-like protein 1, Tec - technique, MBI - microparticle-based immunoassay, ELISA - enzyme-linked immunosorbent assays, MCI - mild cognitive impairment, NR - not reported